

14P15 Rec'd 18 NOV 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned 90/558276
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	5	Attorney Docket Number	05986/100M536-US#1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/AB/	AA*	US-6,440,423	08-27-2002	Clements et al.	
/AB/	AB*	US-6,436,407	08-20-2002	Clements et al.	
/AB/	AC*	US-6,019,982	02-01-2000	Clements et al.	
/AB/	AD*	US-5,843,446	12-01-1998	Ladd et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
/AB/	BA	WO 03/045128	06-05-2003	FRANGIONE, Blas		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					T ⁷
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
/AB/	CA	Jackson and Collinge, Mol Pathol. 2001;54:393-399			
/AB/	CB	Gajdusek and Zigas, N. Eng. J. Med., 1957;257:974-978			
/AB/	CC	Gajdusek and Zigas, Am. J. Med., 1959;26:442-469			
/AB/	CD	Prusiner et al., Prion Protein Biology, 1998;93:337-348			
	CE	Gerstmann et al., Z Neurol., 1990;154:796-792			
/AB/	CF	Ghetti et al., Proc. Natl. Acad. Sci. USA, 1996;93:744-748			
/AB/	CG	Ghetti et al., Mol. Neurobiol., 1994;8:41-48			
/AB/	CH	Medori et al., N. Eng. J. Med., 1992;326:444-449			
/AB/	CI	Goldfarb et al., Science, 1992;258:806-808			
/AB/	CJ	Collinge, Hum. Mol. Genet, 1997;6:1699-1705			
/AB/	CK	Collinge et al., Nature, 1996;383:685-690			
/AB/	CL	Collee and Bradley, Lancet, 1997;349:636-641			
/AB/	CM	Will et al., Lancet, 1997;347:921-925			
Examiner Signature	/Agnieszka Boesen/			Date Considered	12/04/2007

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	Not Yet Assigned 10/558276	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Thomas Wisniewski	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	5	Attorney Docket Number	05986/100M536-US1

/AB/	CN	Griffith, Nature, 1967;215:1043-1044	
/AB/	CO	Horwich and Weismann, Cell, 1997;89:499-510	
/AB/	CP	Prusiner, Science, 1982;216:136-144	
/AB/	CQ	Kretzschmar et al., Am. J. Pathol., 1986;122:1-5	
/AB/	CR	Pocchiari et al., J. Gen. Virol., 1987;68(Pt 1):219-223,	
/AB/	CS	Caughey and Race, J. Neurochem., 1992;59:768-771	
/AB/	CT	Ladogana et al., J. Gen. Virol., 1992;73(Pt 3):661-665	
/AB/	CU	Tagliavini et al., Science, 1997;276:1119-1122	
/AB/	CV	Soto et al., Lancet, 2000;355:192-197	
/AB/	CW	Priola et al., Science, 2000;287:1503-1506	
/AB/	CX	Aucouturier et al., Clin. Immunol, 2000;96:79-85	
/AB/	CY	Aucouturier et al., J. Clin. Invest., 2001;108:703-708	
/AB/	CZ	Wisniewski et al. Curr. Neurosci Reports 2002;2:400-4	
/AB/	CA1	Biochem. Soc. Transact. 2002;30:574-578	
/AB/	CB1	Sigurdsson et al., Am J Pathol 2002;161:13-17	
/AB/	CC1	Sigurdsson et al., Neurosci Lett, 2003;336:185-187	
/AB/	CD1	Steinberg, New Scientist, 2002; 16:22	
/AB/	CE1	Munch et al., J. Neural Transm., 2002;109:1081-1087	
/AB/	CF1	Schenk, Nat. Rev. Neurosci., 2002;3:824-828	
/AB/	CG1	White et al., Adv. Exp. Med. Biol., 1991;303:207-210	
/AB/	CH1	Lauterslager et al., Vaccine, 2003;21:1391-1399	
/AB/	CI1	Foss et al., Animal Health Research Reviews, 2000;1:3-24	
/AB/	CJ1	Sethi et al., Lancet, 2002;360:229-230	
/AB/	CK1	Mannino and Gould-Fogerite, Pharm. Biotechnol., 1995;6:363-87	
/AB/	CL1	Kaneko et al., J. Mol. Biol., 2000;295:997-1007	
/AB/	CM1	Peretz et al., Nature, 2001;412:739-743	
/AB/	CN1	E Cunha-Neto et al., PNAS, 1995;92:3541-3545	

Examiner Signature	/Agnieszka Boesen/	Date Considered	12/04/2007
-----------------------	--------------------	--------------------	------------

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned 10/558276
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	3	of	5	Attorney Docket Number	05986/100M536-US 1

/AB/	CO1	E. Cunha-Neto et al., J. Clin. Invest., 1996;98:1709-1712	
/AB/	CP1	Chabalgoity et al., Vaccine, 2000;19:460-469	
/AB/	CQ1	Pasetti et al., Clin. Immunol., 1999;92:76-89	
/AB/	CR1	Hoiseth et al., Nature, 1981;291:238-239	
/AB/	CS1	Chatfield et al., Vaccine, 1992;10:53-60	
/AB/	CT1	Benkirane et al., J. Biol. Chem., 1993;268:26279-26285	
/AB/	CU1	Ben-Yedidia et al., Mol. Immunol., 2002;39:323-331	
/AB/	CV1	Ripka et al., Curr. Opin. Chem. Biol., 1998;2:441-452	
/AB/	CW1	Spatola, In: Chem. Biochem. Amino Acids, Pept., Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; pp. 267-357	
/AB/	CX1	Hart and Rich, In: Pract. Med. Chem.; Wermuth, C., Ed., Acad. Press: London, U.K., 1996; pp. 393-412	
/AB/	CY1	Farmer, In: Drug Design; Ariens, E.J., Ed.; Academic Press: New York, 1980; 10:119-143	
/AB/	CZ1	Fletcher and Campell, Chem. Rev., 1998;98:763-795	
/AB/	CA2	Chabalgoity et al., Exp. Rev. Vaccines, 2002;1:495-505	
/AB/	CB2	Mastroeni et al., Veterinary Journal, 2001;161:132-164	
/AB/	CC2	Cardenas and Clements, Clin. Microbiol. Rev., 1992;5:328-342	
/AB/	CD2	Clements et al., 1992, In: Recombinant DNA Vaccines: Rationale and Strategy, Isaacson (ed.), Marcel Decker, New York. pp. 293-322;	
/AB/	CE2	Clements and Cardenas, Res. Microbiol., 1990;141:981-993	
/AB/	CF2	Sanitago et al., Pharmaceutical Research, 1993;10:1243-1247	
/AB/	CG2	Alving et al., Vaccine, 1986;4:166-172	
/AB/	CH2	Garcon and Six, J. Immunol., 1991;146:3697-3702	
/AB/	CI2	Gould-Fogerite and Mannino, 1993, In: Liposome Technology 2nd Edition. Vol. III, Gregoriadis (ed.)	
/AB/	CJ2	Mowat and Donachie, Immunology Today, 1991;12:383-385	
/AB/	CK2	Baylor, NW et al., Vaccine, 2002;20 Suppl 3:S18-23	
/AB/	CL2	Clements et al., Vaccine, 1988;6:269-277	
/AB/	CM2	Elson, Immunology Today, 1989;146:29-33	
Examiner Signature	/Agnieszka Boesen/		Date Considered 12/04/2007

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned 10/558276
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	4	of	5	Attorney Docket Number	05986/100M536-US1

/AB/	CN2	Lycke and Holmgren, Immunology, 1986;59:301-308	
/AB/	CO2	Lycke et al., Eur. J. Immunol., 1992;22:2277-2281	
/AB/	CP2	Tamura et al., Japanese Journal of Infectious Diseases, 2000;53:98-106	
/AB/	CQ2	Finkelstein and LoSpalluto, J. Exp. Med., 1969;130: 185-202	
/AB/	CR2	Elson and Ealding, J. Immunol., 1984;133:2892-2897	
/AB/	CS2	Fujihashi et al., Acta Odontologica Scandinavica, 2001;59:301-308	
/AB/	CT2	Czerkinsky et al., Proc. Natl. Acad. Sci. (USA), 1989;57:1072-1077	
/AB/	CU2	Pierce et al., Infect. Immun., 1983;40: 1112-1118	
/AB/	CV2	Cebra et al., 1986, In: Vaccines 86, Brown et al. (ed.), Cold Spring Harbor Laboratory, New York. p.p. 129-133	
/AB/	CW2	McKenzie and Halsey, J. Immunol., 1984;133: 1818-1824	
/AB/	CX2	McCarthy et al., J. Immunol. Methods, 1985;82:349-358	
/AB/	CY2	McCarthy D.A. and Drake, A.F., Mol. Immunol., 1989;26(9):875-881	
/AB/	CZ2	Tacket et al., Infection and Immunity, 2000 Mar;68(3):1196-1201	
/AB/	CA3	Kotloff et al., Infect. Immun., 2002;70:2016-21	
/AB/	CB3	Lillard et al., Cellular and Molecular Biology, 2001;47:1115-1120	
/AB/	CC3	Levine et al., Journal of Biotechnology, 1996;44:193-196	
/AB/	CD3	Nardelli-Haeffliger et al., Infection and Immunity, 1996;64:5219-5224	
/AB/	CE3	Tacket et al., Infection and Immunity, 1997;65:452-456	
/AB/	CF3	O'Hagan et al. (Immunology 1991;73:239-42	
/AB/	CG3	Sigurdsson et al. (Am J Pathol 2001;159:439-447	
/AB/	CH3	Sobotka et al., Pharmacology, 1978;16:287-294	
/AB/	CI3	Quarternain et al., Neurosci. Lett., 2000;288:155-158	
/AB/	CJ3	Ammassari-Teule et al., Behav. Brain Res., 1985;17:9-16	
/AB/	CK3	Rouillet et al., Physiol. Behav., 1998;64:203-7	
/AB/	CL3	Rouillet et al., Physiol. Behav., 1995;58:1189-95	

Examiner Signature	/Agnieszka Boesen/	Date Considered	12/04/2007
-----------------------	--------------------	--------------------	------------

18 NOV 2005

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned 10/558276
				Filing Date	Concurrently Herewith
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	5	of	5	Attorney Docket Number	05986/100M536-US1

/AB/	CM3	Knobel et al., J. Wildl. Dis., 2002;38:352-62	
/AB/	CN3	Carp and Rubenstein, Semin. Virol 1991;2:203-213	
/AB/	CO3	Kascsak et al., J Virol, 1986;59: 676-683	
/AB/	CP3	Sigurdsson et al., TIMM, 2002;8:411-413	
/AB/	CQ3	Chabalgoity et al., Mol Microb., 1996;19(4):791-801	
/AB/	CR3	Clements and El-Morshidy, Infect. Immun., 1984; 46:564-569	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Agnieszka Boesen/	Date Considered	12/04/2007
-----------------------	--------------------	--------------------	------------



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete If Known	
				Application Number	10/558,276
				Filing Date	November 18, 2005
				First Named Inventor	Thomas Wisniewski
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	05986/100M536-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/AB/	CA	M. H. Groschup et al. "Studies on Species-specific Epitope in Murine, Ovine and Bovine Prion Protein" Journal of General Virology, 1993, Vol 74, pages 1451-1456	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Agnieszka Boesen/	Date Considered	12/04/2007
-----------------------	--------------------	--------------------	------------